Loading...
XSHE
300676
Market cap3.04bUSD
Sep 17, Last price  
51.79CNY
1D
-1.26%
1Q
7.94%
IPO
139.77%
Name

BGI Genomics Co Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
5.58
EPS
—
Div Yield, %
0.19%
Shrs. gr., 5y
0.61%
Rev. gr., 5y
6.67%
Revenues
3.87b
-11.10%
794,839,3481,047,380,6461,131,981,8471,318,703,6231,711,498,2532,095,544,2712,536,406,1052,800,411,9368,397,230,0026,766,137,3157,046,132,0814,349,637,2503,866,920,764
Net income
-903m
L
81,734,191135,880,89728,120,733262,099,904332,690,944398,091,510386,645,517276,334,0182,090,285,2731,461,536,272802,765,40892,900,396-902,690,862
CFO
96m
-76.58%
72,488,80036,701,6000328,682,815234,073,624226,570,84714,687,326224,254,9613,602,692,5312,476,132,383136,378,792408,767,85195,722,825
Dividend
Jul 04, 20240.1 CNY/sh

Profile

BGI Genomics Co., Ltd. provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally. The company offers DNA, RNA, and customized sequencing services; and non-invasive prenatal testing, reproductive health screening, newborn genetic screening, and clinical exome sequencing services, as well as clinical and research solutions for oncology. It also offers laboratory solutions for the detection and diagnosis of patients suspected with COVID-19; SARS-CoV-2 IgM and IgG antibody detection kit; and real-time fluorescent RT-PCR kit for detecting SARS-CoV-2. The company offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. BGI Genomics Co., Ltd. was founded in 1999 and is headquartered in Shenzhen, China.
URL
https://www.bgi.com/
IPO date
Jul 14, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,866,921
-11.10%
4,349,637
-38.27%
7,046,132
4.14%
Cost of revenue
3,566,337
3,386,221
5,642,406
Unusual Expense (Income)
NOPBT
300,584
963,416
1,403,726
NOPBT Margin
7.77%
22.15%
19.92%
Operating Taxes
25,986
21,854
197,515
Tax Rate
8.65%
2.27%
14.07%
NOPAT
274,598
941,562
1,206,211
Net income
(902,691)
-1,071.68%
92,900
-88.43%
802,765
-45.07%
Dividends
(50,363)
(143,470)
Dividend yield
0.29%
0.68%
Proceeds from repurchase of equity
(727,446)
82,851
(299,268)
BB yield
4.20%
-0.42%
1.41%
Debt
Debt current
24,912
24,184
809,536
Long-term debt
438,508
351,176
273,360
Deferred revenue
15,106
19,675
Other long-term liabilities
15,393
1
Net debt
(4,777,618)
(5,609,274)
(5,403,210)
Cash flow
Cash from operating activities
95,723
408,768
136,379
CAPEX
(529,481)
Cash from investing activities
(314,416)
(1,750,741)
Cash from financing activities
(683,152)
(266,882)
FCF
610,831
183,137
173,909
Balance
Cash
4,309,677
5,485,951
6,389,691
Long term investments
931,361
498,682
96,416
Excess cash
5,047,692
5,767,152
6,133,800
Stockholders' equity
4,226,286
5,176,682
5,978,621
Invested Capital
5,474,151
5,150,343
5,085,663
ROIC
5.17%
18.40%
22.60%
ROCE
3.09%
9.32%
12.63%
EV
Common stock shares outstanding
412,369
412,341
409,914
Price
41.97
-12.56%
48.00
-7.14%
51.69
-41.13%
Market cap
17,307,113
-12.56%
19,792,361
-6.59%
21,188,464
-41.38%
EV
12,666,248
14,327,870
15,930,343
EBITDA
784,113
1,400,252
1,856,761
EV/EBITDA
16.15
10.23
8.58
Interest
56,293
91,560
100,764
Interest/NOPBT
18.73%
9.50%
7.18%